A phase III, randomized, open label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine plus cisplatin (G plus C) for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (MIBC) (NIAGARA) Meeting Abstract
| Authors: | Powles, T.; Meeks, J. J.; Galsky, M. D.; Van der Heijden, M. S.; Nishiyama, H.; Al-Ahmadie, H.; Gupta, A. K.; Ye, J.; Donegan, S. E.; Ghiorghiu, D. C.; Ferro, S.; Catto, J. W. F. |
| Abstract Title: | A phase III, randomized, open label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine plus cisplatin (G plus C) for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (MIBC) (NIAGARA) |
| Meeting Title: | 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 37 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2019 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2019-05-20 |
| Start Page: | 286s |
| Language: | English |
| ACCESSION: | WOS:000487345803359 |
| DOI: | 10.1200/JCO.2019.37.15_suppl.TPS4592 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS4592 -- Source: Wos |
